An immunodominant epitope of myelin basic protein (MBP), VHFFKNIVTPRTP (p87-99), is a major target of T cells in lesions of multiple sclerosis (MS) and in experimental allergic encephalomyelitis (EAE). T cells found in EAE lesions bear the same amino acids in the third complementary determining region of the T cell receptor (TCK) as those found in MS lesions. We analyzed the trimolecular interactions between MBP p87-99, dass II major histocompatibility complex (MHC), and TCK, and designed soluble inhibitors for therapy. F, N, I, and V at positions 90, 92, 93, and 94 interact with MHC, whereas K, T, and P at positions 91, 95, and 96 interact with TCK. The peptides, p87-99195T>A] and p87-99196P>A] could compete more effectively with p87-99 for binding to MHC and could antagonize the in vitro response ofT cells to p87-99 more effectively than p87-99191K>A]. However, only p87-99191K>A] prevented and reversed EAE, indicating that the extent of MHC or TCK competition does not predict success in treating EAE. To elucidate the mechanism of inhibition of EAE, draining lymph node cells from rats immunized with the native peptide alone or together with each of the three TCR antagonists were challenged in vitro with p87-99. Administration of p87-99191K>A], but not p87-99 [9ST>A] or p87-99196P>A], reduced the production of tumor necrosis factor (TNF)-oe and interferon (IFN) 3'. IFN-3" and TNF-ol are two cytokines that are critical in the pathogenesis of EAE and MS.
xperimental allergic encephalomyelitis (EAE) 1 is a T cellmediated autoimmune disease of the central nervous system (1, 2) . The TCK recognizes peptide bound to an MHC molecule (3) . Several groups, including ours, have formulated nonimmunogenic peptides based on the sequence of myelin basic protein (MBP) that bind class II MHC to a much greater extent than the native, encephalitogenic peptides of MBP, and that prevent EAE when given in adjuvant (4) (5) (6) (7) (8) (9) . We now extend this approach in order to develop TCR. antagonists that would prevent and reverse EAE, when induced by MBP p87-99.
The rationale for pursuing inhibitors of the MBP p87-99 follows from some serendipitous findings (10) regarding a major set of TCR rearrangements in multiple sclerosis (MS) brain lesions. Using PCK on reverse-transcribed mRNA, we 1 Abbreviations used in this paper: EAE, experimental allergic encephalomyelitis; MBP, myelin basic protein; MS, multiple sclerosis; PLP, proteolipid protein; SI, stimulation index.
analyzed TCK gene rearrangements directly from brain plaques of MS patients, who are HLA DK2 (10) , and from spinal cords of rats with EAE after immunization with p87-99 (11) . T cells with the amino acid motif LRG in the CDR3 region (10) (11) (12) (13) are found in EAE lesions in the Lewis rat and in MS lesions. Remarkably, a cytotoxic T cell clone specific for MBP p87-99 from an MS patient who was HLA DR2 has the same amino acid motif, LRG, in the CDK3 of its TCK-3 chain (12, 14) . Thus, T cell clones in Lewis rats and in MS patients, which express this CDR3 motif, all have specificity for MBP p87-99, VHFFKNIVTPKTP (p87-99) (10, 11, 14) . MBP p87-99 has further importance because it is an immunodominant epitope of MBP in MS patients who are HLA DR2 (10, 11, 14, 15) .
We have analyzed the putative sites where MBP p87-99 interacts with MHC and TCR in the Lewis rat. Based on these studies, we designed different peptide antagonists of MBP 87-99 that interfere with the encephalitogenic T cells. We have been able to design a peptide inhibitor that an-tagonizes the pathogenic T cells and when administered in soluble form, can reverse ongoing EAE with clinical paralysis. This peptide also reduces production of two critical cytokines involved in the pathogenesis of EAE and MS, TNF-oe and IFN-'y. This report extends the approach of using TCP, antagonists to prevent EAE (4, 5, 8, 16) . Recently, Franco et al. (16) showed that they could prevent EAE with a pool of TCR antagonist peptides given in equimolar amounts with the encephalitogenic peptide 139-151 of proteolipid protein (PLP) in CFA. We sought to apply this approach to a clinically relevant paradigm in which we attempted to reverse established paralysis with a TCR antagonist that could be given in a soluble form.
Materials and Methods
Rats. Female Lewis rats, •6 wk old, were purchased from Harlan Sprague Dawley (Indianapolis, IN).
Peptide Antigens. Human MBP p87-99, VHFFKNIVTPRTP, and a series of 13 p87-99 analogues that differ from the original MBP peptide by a single alanine substitution, as well as MBP pl-20 and MBP p68-86, were synthesized with a free carboxylic acid at the COOH terminus on a peptide synthesizer (model 9050; MilliGen, Burlington, MA) by standard 9-fluorenylmethoxycarbonyl chemistry. MBP pl-20 is acetylated at the NH2 terminus. Peptides were purified by HPLC. Structure was confirmed by amino acid analysis and mass spectroscopy. Only peptides that were >95% pure were used in our study.
Immunizations and Active EAE Induction. MBP peptides were dissolved in PBS and emulsified with an equal volume of IFA supplemented with 4 mg/ml heat-killed MIcobacterium tuberculosis H37Ra in oil (Difco Laboratories, Detroit, MI). Rats were immunized subcutaneously in the hind foot pads with 0.1 ml of the emulsion and were monitored daily for clinical signs by an observer blind to the treatment protocol. EAE was scored as follows: 0, clinically normal; 1, flaccid tail; 2, hind limb paralysis; and 3, front and hind limb paralysis.
Culture Media. DME (GIBCO BILL, Gaithersburg, ME)) supplemented with 2-ME (5 x 10 -s M), t-glutamine (2 mM), sodium pyruvate (1 raM), penicillin (100 #/ml), streptomycin (100 #g/ml), and 1~ autologous Lewis rat serum was used as a stimulation medium. Resting medium was identical to the stimulation medium without autologous serum and with the addition of 10% FCS (GIBCO BILL) and 12.5% supernatant of Con A-stimulated splenocytes as a source of T cell growth factors. Con A supernatant was prepared as described elsewhere (1).
Antigen-specific T Cell Proliferation Assays. Lewis rats were immunized with different MBP peptides as described above. 9-10 d later, draining lymph node cells were suspended in stimulation medium and cultured in U-shape 96-well microcuhure plates for 72 h at 37~ in humidified air containing 6.5% CO2, at a concentration of 2 x l0 s cells/well. For the antigen-specific proliferation assay ofT celt lines and clones, ceils were plated at a concentration of 2 x 104 cells/well with l0 s irradiated (2,500 rad) thymocytes as accessory cells together with different concentrations of ,ntigen. Each well was pulsed with 2/~Ci of [3H]thymidine (sp act 10 Ci/mmol) for the final 6 h. The cultures were then harvested on fiberglass falters and the proliferative response expressed as cpm _+ SD or as stimulation index (SI) (mean counts per minute test cultures divided by mean counts per minute control cultures).
Long-term T Cell Lines and Clones.
Antigen-specific long-term T cell lines and dones were deriv&l by use of the method developed by Ben-Nun et al. (1) . Lewis rats were immunized as described previously. 9-10 d later, draining lymph node calls were cultured (107/ml) for 72 h in stimulation medium together with 10-20 /~mol of the immunizing peptide. The cells were then collected, washed, and cultured for a phase in resting medium. After an additional 5-8 d, cells were collected and either tested for antigen-specific proliferation or cultured for additional cycles. For cloning of antigenspecific T cell lines, resting T cells were cultured in 96-well microculture plates at a concentration of 0.3 cells/well with 5 x 10 s irradiated (2,500 tad) thymocytes as accessory cells and 10-20 #mol of antigen. After three to five stimulation cycles, plates were screened, clones were transferred to 24-well flat bottom plates, and restimulated. Before use in the study, all clones were recloned by use of the method described above.
MHC Binding
Assay. An assay that characterizes the binding of peptides to MHC molecules on living APCs was used (17, 18) . Spleen cells were cultured in DME supplemented with 10% FCS (Hyclone Laboratories, Logan, UT) in standard polystyrene petri dishes (100 x 15 mm; Baxter Healthcare Corp., Deerfield, IL) in a 37~ incubator containing 6.5% CO2 for 3 h. Thereafter, nonadherent cells were removed, and the plates were washed three times with PBS. Adherent cells were collected with a cell scraper (Falcon, Franklin Lakes, NJ). The binding of p87-99 analogues was measured by use of a fluorescence assay as follows: 5 x 10 s splenic adherent cells in staining buffer containing 0.1% BSA in PBS were mixed with different concentrations ofp87-99 analogues in individual wells of U-shape 96-well microculture plates and incubated at 370C in a 6.5% CO2 incubator. I h later, biotinqabeled p87-99 (10 #mol) was added to culture wells for 4 h. Cytokine Determination. Draining lymph node cells were stimulated in vitro (10 7 calls/m1) with different concentrations of antigens. After 12, 24, 48 , and 72 h of stimulation, supernatants were collected for cytokine detection, and cells were immediately frozen for KNA extraction. IFN-y was determined after 48 h by use of a rat IFN-'y ELISA kit (GIBCO BRL). TNF-~x was measured after 24 h by use of ELISA kits (Genzyme Corp., Cambridge, MA) suitable for mice and rats. The kits were used according to manufacturers' instructions.
Results

Determination of Amino Acids Involved in the Binding ofp87-99 to RT.D 1 (IF.) MHC Class II Molecules. A single injection
of guinea pig MBP emulsified in CFA induces EAE in the Lewis rat (1). The T cell response is directed against a major encephalitogenic region encompassed by residues 68-86 presented in association with RT.B 1 (I-A) MHC class II molecules (20) , and to a second encephalitogenic region encompassed by a residues 87-99 of MBP restricted by RT.D 1 (I-E) MHC class II gene products (20, 21) . A T ceU line specific for p87-99, named L87-99, was selected. The proliferative response of the line was blocked to a substantial degree with an anti-I-E (OX-17, 2.5/zg/ml), but not an anti-I-A (OX-6, 2.5/~g/ml) mAb (response to MBP p87-99:54,350 + 840 with anti-I-A blocking vs. 17,120 _+ 310 with anti-I-E blocking [data shown as cpm __ SE, background: 3,420 __ 330 cpm, p <0.001]). A panel of 13 alanine-substituted peptides based on MBP p87-99 was synthesized (Table 1 ). These analogues were tested in a competition assay with the native peptide for binding to I-E on APCs ( Fig. 1 , Table 1 ). Four of these peptides, p87-99190F>A], p87-99192N>A], p87-99 [93I>A], and p87-99194V>A], were poor competitors with the native peptide on binding to autologous APCs (ICso >200/~M for each of the analogues, compared with ICs0 = 14/~M for the native peptide) ( Table 1) . These results indicate that these four positions are putative binding sites to I-E (see Fig. 3 ).
Amino Acids Necessary for Induction of EAE. Each of 13
alanine-substituted analogues was tested for its ability to induce EAE (Table 1 Fig. 1 ), (range of ICs0 14-21 compared with ICs0 native peptide of 14), never induced EAE in Lewis rats (Table  1 , incidence of 0.6 for each of these analogues compared with 6/6 for the native peptide). This suggests that lysine, threonine, and proline at positions 91, 95, and 96 are essential for TCR recognition of p87-99.
All three nonencephalitogenic peptide analogues that bound to I-E with ICs0 in the range of native peptide, p87-99 [91K>A], p87-99195T>A], and p87-99196P>A], either stimulated a weak response to p87-99 or failed to elicit a proliferative response in L87-99 (Fig. 2) . This further confirms our observation that the lysine, threonine, and proline at positions 91, 95, and 96 are essential for effective TCR binding to p87-99 (Figs. 2 and 3). Consequently, each of these analogues might serve as a therapeutic TCR antagonist capable of blocking EAE. The peptides p87-99197R>A] and p87-99 [98T>A] were encephalitogenic and could evoke a proliferative response in draining lymph node T cells after immunization with native p87-99 (Table 1) , though they failed to elicit a significant proliferative response in L87-99 (Fig. 2) . This indicates that L87-99 does not include all potential T cell clones capable of mounting a pathogenic T cell response. Peptide Concentration (pM) Table 1 . (Fig. 4 A) . These findings could be explained in part by the fact that both p87-99195T>A] and p87-99196P>A] are stronger competitors of the native peptide on binding I-E than p87-99191K>A] (IC50 = 14 for each of these peptides compared with IC50 = 21 for p87-99191K>A]) (Fig. 1) . All three peptide analogues antagonized the proliferative response of the encephalitogenic line L87-99 (Fig. 4) . We also tested each of these antagonists on an anti-p87-99 CD4 + T cell clone selected from this line. A representative experiment with this clone revealed a proliferative response of 12,336 _+ 440 cpm with a background of 458 cpm in response to 0. Peptide Concentration Figure 2 . Proliferative response of L87-99 to different alanine-substituted analogues. The proliferative response of L87-99 in response to the different alanine-substituted analogues was determined in a proliferation assay and shown as counts per minute. All standard deviations were less than _+10%.
Comparison of the TCR
a control peptide, since in Lewis rats this peptide is not encephalitogenic (Table 2 , group l). Coimmunization of the pl-20 fragment together with p87-99 did not prevent EAE in any of the immunized rats (6/6 with EAE; Table  2 , group m). In Lewis rats there are two encephalitogenic regions of MBP, p68-86 and p87-99. We studied the specificity of EAE inhibition by p87-99191K>A]. Rats were coimmunized with either p87-99 plus p87 
Mechanisms of Inhibition of EAE by p87-99191K>A].
To further investigate the mechanism behind EAE resistance, rats were immunized with native peptide p87-99 alone, or together with either peptide p87-99191K>A], p87-99195T>A], or p87-99196P>A] at a 1:1 molar ratio with the native peptide, p87-99. 9 d later, some of the rats were killed, and proliferative responses against the native peptide were determined in the draining lymph nodes (Fig. 5, A and B) . Some rats from each of the groups remained in cages for further observation for development of paralysis. All rats (6/6) immunized with the native peptide alone or p87-99 together with either p87-99195T>A] or p87-99196P>A] developed EAE. None of the rats coimmunized with p87-99191K>A] and p87-99 developed EAE (0/6, p <0.001). Nevertheless, all groups displayed a very similar SI (Fig. 5 B) in the proliferative response against the native peptide, p87-99, in their draining lymph node cells. We noted that the proliferative response to p87-99 (in absolute counts per minute) observed in draining lymph node cells from rats immunized with the native peptide alone was lower than the proliferative response seen in lymph nodes from rats coimmunized with p87-99
[91K>A], p87-99195T>A], or p87-99196P>A] (Fig. 5, A and B). These results indicate that EAE resistance did not result from induction of unresponsiveness to the native, pathogenic peptide when rats were coimmunized with native peptide and p87-99191K>A]. We hypothesized that the protective and nonprotective TCR antagonists might differentially alter the cytokine profile in encephalitogenic T cells after stimulation with the pathogenic peptide. The draining lymph node cells from rats coimmunized with p87-99 and p87-9919LK>A] produced markedly reduced levels of TNF-o~ and IFN-'y compared with those immunized with the native peptide or coimmunized with p87-99195T>A] or p87-99196P>A]. For IFN-% we observed the following amounts in response to 100 #M p87-99 in vitro (Fig. 5 C) : 1,750 _+ 80 pg/ml when p87-99191K>A] was coimmunized with native p87-99, compared with 5,200 _+ 300 pg/ml for p87-99195T>A] plus p87-99 (p <0.0015); 7,200 _+ 580 pg /ml for p87-99196P>A] plus p87-99 (p <0.001); and 4,200 _+ 100 pg/ml for native peptide alone (p <0.003). For TNF-o~, we observed the following amounts in response to 100 #M p87-99 in vitro (Fig. 5 D) : 32 _+ 3 pg/ml when p87-99191K>A] was coimmunized with native p87-99, compared with 81 _+ 4 pg/ml for p87-99 [95T>A] plus p87-99 (p <0.003); 72 _+ 4 pg/ml for p87-99 [96P>A] plus p87-99 (p <0.004); and 62 _+ 1 pg/ml when p87-99 was given alone (p <0.005). Thus the TCR antagonist capable of blocking EAE, p87-99191K>A], reduced TNF-ol and IFN-'y production, whereas the other TCR antagonists did not influence the production of these cytokines.
Reversal of EAE by Soluble Peptide Analogues. From aclinical
perspective, the use of a soluble form of a therapeutic peptide analogue would be more practical than the use of such a peptide emulsified in CFA. We therefore explored the therapeutic potential of soluble p87-9919LK>A]. In experiment 1 (Table  3) In experiment two (Table 3) , two i.p. injections of 2 mg/ml each were given on days 2 and 4 after transfer of L87-99. Peptides p87-99, p87-99191K>A], and p87-99196P>A] reduced the incidence of EAE: on day 7 in the group of control rats, 6/6 had EAE, but when p87-99 was given intraperitoneally in solution, 0/6 had EAE (p <0.001 compared with control animals), when p87-99[K91>A] was given intraperitoneally in solution, 0/6 had EAE (p <0.001 compared with control rats), and when p87-99196P>A] was given intraperitoneally in solution, 2/6 had EAE (p <0.15 compared with control rats). In comparison, when p87-99195T>A] was given intraperitoneally in solution, 6/6 had EAE.
Disease reversal was attempted in a third experiment in which 15 rats were inoculated with 15 x 106 L87-99 cells to induce EAE and were randomly distributed into three subgroups of 5 rats each. 1 d later, two of these groups were given intraperitoneaUy 2 mg/ml of p87-99191K>A] dissolved in PBS. All 15 rats had hind limb paralysis 4-5 d after disease induction. On day 5, one group received another 2 mg/ml of p87-99191K>A]. All 5 rats who received this second infusion of p87-99191K>A] went into complete remission within 24-36 h, with no residual signs of paralysis, whereas paralysis persisted in all other rats for another 4-5 d.
In a fourth experiment (Fig. 6 ), 18 rats were given 107 L87-99 T cells, and all 18 developed hind limb paralysis within (Fig. 6 ).
Discussion
Activation of CD4 § T cells follows engagement of the TCR by a peptide bound to class II MHC (3), together with a costimulatory signal from the APCs (22) . Optimal engagement leads to proliferation, cytokine induction, and effector function. Previous studies have shown that analogues of a native peptide in which a critical TCR binding site was altered may perturb the effector functions of the T cell, including alterations in proliferative capacity and cytokine production (22) (23) (24) (25) . In this study, we have continued our studies on the design of peptide-based TCR antagonists to reverse the prototypic model of CD4 + T cell-mediated autoimmunity, EAE (9) .
We and others (4, 5, 8, 9) have previously formulated nonpathogenic peptide analogues that bind class II MHC to a much greater extent than the native encephalitogenic peptides of MBP and prevent EAE in a specific manner. It has been assumed that the main, if not the only, mechanism by which these peptides inhibit EAE is by successfully competing with the native peptide for binding to MHC class II (26) . However, further evidence suggested that mechanisms other than MHC competition might be involved in this process. In the Lewis rat, the major encephalitogenic region encompasses residues 68-86 presented in association with RT.B 1 (I-A) MHC class II molecules (20) . Arthritogenic T cells recognize their autoantigen in association with RT.B 1 gene products as well (27) . Wauben et al. (27) have used high MHC-binding peptide analogues of either the encephalitogenic or arthritogenic peptides to show that arthritis could be blocked only by the arthritogenic peptide analogue, whereas EAE could be blocked by either peptide. These findings implied that mechanisms distinct from MHC blocking are operative in this form of immunotherapy (27) .
In (PL/JxSJL) mice, EAE is induced by immunization with MBP peptide Ac1-11. Q and K at positions 3 and 4 in this MBP epitope are putative TCR-and MHC-binding sites, respectively (8) . Mutations in peptides with either single alanine substitutions at position 4K or double substitutions at both 3Q and 4K resulted in nonencephalitogenic peptides with an enhanced capacity to compete with the native Acl-ll (19) have demonstrated that peptide analogues, mutated in a TCR putative binding site, may display variable degrees of antagonism toward a collection of T cell clones with similar antigen specificity and MHC restriction (19, 28, 29) . A recent paper by Franco et al. (16) examined some peptide analogues, mutated in their TCR binding sites for their potential capability to prevent EAE, when induced by p139-151 of PLP in vivo. No single mutated peptide could antagonize the response of the majority of these PLP clones in vitro. Therefore, they used a pool of TCR antagonists to block the proliferative response of different T cells specific for PLP p139-151. They successfully prevented EAE induction when the antagonists were coadministered in adjuvant at the time of immunization (16) . Neither disease reversal nor the use of water soluble inhibitors in vivo was demonstrated.
We tested the therapeutic capabilities of three alaninesubstituted analogues, mutated in a putative TCR binding site. All three peptide analogues antagonized the proliferative response of the encephalitogenic line L87-99 (Fig. 4) , as well as an anti-p87-99 CD4 + T cell clone selected from this line. Nevertheless, only one of these antagonists could prevent and reverse EAE. In addition, in draining lymph node cells from rats immunized with the inhibitory analogue, there was no reduction in the proliferative response to the pathogenic peptide p87-99 (Fig. 5) . This reinforces the idea that EAE resistance does not result from antigen unresponsiveness to p87-99. We hypothesized that the protective and nonprotective antagonists may differentially alter the cytokine profile in the encephalitogenic T cells. Indeed, we have demonstrated that only rats coimmunized with p87-99 and the protective p87-99191K>A], and not p87-99195T>A] or 87-99 [96P>A], could downregulate the production of the Thl cytokines, TNF-ol and IFN-% The role of TNF-oe in EAE has been studied extensively (30) (31) (32) (33) (34) . Administration of TNF-cz augmented EAE (31), whereas anti-TNF-ol therapy abrogated the disease (33, 34) . The capacity of autoimmune T cell clones to induce EAE was found to be corrdated with their ability to produce TNF-cz (32) . In different strains of rats susceptibility to EAE was . EAE was monitored daily as described in Table 2 . Experiment 2: Rats were inoculated intraperitoneally with 10 x 106 activated L87-99 cells (day 0) and were randomly distributed into five subgroups of six rats each. Two injections of 2 mg/ml of either p87-99, p87-99191K~,A], p87-99[95T>A], or p87-99196P>A] were given intraperitoneally on days 2 and 4. EAE was monitored daily as described in Table 2. correlated with TNF-ot expression by astrocytes (30) . Elevated levels of TNF-ct in the cerebrospinal fluid have been associated with disease progression in MS (35) .
The role of IFN-3, in EAE is enigmatic. It is a potent activator of monocytes and macrophages and an inducer of class II expression on astrocytes. Blockade of MHC class II prevents and reverses EAE (36, 37) . In EAE, astrocytes may present MBP to encephalitogenic T cells (38) . In contrast, intraventricular administration of IFN-3, suppressed EAE in Lewis rats (39) , perhaps by eliciting the activation of macrophages, thus resulting in elevated levels of TGF45 secretion, which downregulates TNF-c~ production and thereby suppresses EAE (40) . Anti-IFN-3, antibody also exacerbates EAE (41, 42) . Administration of IFN-T to MS patients induces exacerbations (43). Day Figure 6 . Reversal of EAE by soluble peptide therapy. Rats were immunized with 1071.87-99 cells to induce transferred EAE. 5 d later, when clinical disease was apparent, rats were randomly distributed into three subgroups of six rats each. These groups were then injected intraperitoneally with 2 mg/ml of either p87-99-[91K~A] (~), p87-99195T~A l (-I-), or PBS ('-C~). EAE was graded daily (mean _+ SE) as described in Table 2 .
IFN-3, and TNF-c~ together exhibit a synergistic effect on enhancing expression of adhesion molecules on endothelial cells (44) , and thus act in concert to promote the inflammatory process in the central nervous system. Adhesion molecules such as very late antigen 4 and vascular cell adhesion molecule are critical in the pathogenesis of EAE (45) . These roles for TNF-ot and IFN-q, may explain why p87-99191K~A], in contrast to p87-99195T~A] or p87-99196P>A] p87, prevented and reversed EAE.
Finally, it is remarkable that the injection of a TCR antagonist in soluble form could reverse ongoing paralysis in EAE. The mechanism of this inhibition is unclear at present, but direct binary engagement of the TCR by antigen may be a possibility, even though this idea is perhaps heretical (46) . Binary interactions between superantigen and TCR have been demonstrated (47) . Alternatively, soluble MHC-peptide complexes might act to inhibit EAE by engaging TCR without adequate second signals (48) .
There is therapeutic potential for the delivery of soluble TCR antagonists devoid of adjuvant or MHC, given the dominance of T cell responses to certain peptides in MS (10, 11) . It is noteworthy that the peptide p87-99191K~A] abrogates the cytotoxicity of a human T cell clone, derived from an MS patient who is HLA DR2, that is cytotoxic for MBP p87-99. This clone has the CDR3 motif LRG in the TCR-B chain (49) . Whether suppression of this immune response in an MS patient will alter the course of disease can only be answered in a clinical trial.
It is noteworthy that clinical trials involving the administration of MBE have been undertaken in patients with MS (50, 51) . In one of these trials, some patients became sensitized to the administered MBP (51) . Animal testing of native peptides of MBP given subcutaneously in adjuvant (52) or orally (53) has been promising. We propose here that parenteral administration of modified native peptides devoid of encephalitogenic potential that antagonize TCR involved in the disease will be an advantageous strategy for the therapy of MS.
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